Sep 2021
DDR and PARPi BluePrint documents have been developed under the guidance of a Steering Committee with expertise in the field of DDR and PARP inhibition (PARPi).
These BluePrints are a reference guide to key aspects of PARPi and DDR and their role in oncology.
A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARPi in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARPi.
AstraZeneca and Tesaro.
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
Artios Pharma Ltd.
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
AstraZeneca.
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Duration
MIN
Downloadable resources
Yes
DOWNLOAD DDR BLUEPRINT
DOWNLOAD PARPi BLUEPRINT
Language(s)
Podcast
19 MIN
Jul 2024 
Conference update
Downloadable
03 MIN
Jul 2024 
Podcast
A podcast discussion on treating thrombosis in patients with cancer
Downloadable
14 MIN
Sep 2023 
An interactive patient case video series from breast cancer specialists
15 MIN
Sep 2023 
Publication
Data from an Asia-Pacific patient and HCP survey
Downloadable
5 MIN
Sep 2023 
Video
A video update from Prof. Gerald Prager
Downloadable
4 MIN
Sep 2023 
